CLEVELAND, Oct. 13, 2016 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), makers of the world's first and only clinical MRI-guided radiation therapy system, announced today highlights from the recent 2016 Annual Meeting of the American Society for Radiation Oncology (ASTRO), which featured extensive clinical experience with the company's MRIdian System, as well research highlighting the MRIdian linear accelerator (Linac) technology.

As part of ASTRO's Scientific Sessions, 19 MRIdian clinical presentations and posters were featured from MRIdian users at Washington University and Siteman Cancer Center at Barnes-Jewish Hospital (Washington University); University of California, Los Angeles Health System and Jonsson Comprehensive Cancer Center (UCLA); The University of Wisconsin Carbone Cancer Center (University of Wisconsin); and Seoul National University Hospital, Seoul, South Korea.

Clinical presentations featuring MRIdian
Pancreatic Cancer: Researchers from the University of Wisconsin shared early data from a multi-institutional study examining MRIdian's stereotactic body radiation therapy (SBRT) capabilities, including its role in enabling dose escalation while reducing normal tissue toxicities to areas such as the duodenum and improving tumor control.

- Bladder Cancer: Another study by University of Wisconsin researchers used MRI-based daily patient setup to monitor anatomy in bladder cancer patients. Pre-treatment imaging revealed a reduction in tumor size and potential for increased dose to the bowel over the course of treatment, thereby demonstrating the value of MRIdian's on-table adaptive capabilities in reducing normal tissue toxicity.

- Gynecologic Malignancies: UCLA researchers explored MRIdian's role in delivering intensity modulated radiation therapy (IMRT) for post-operative gynecologic malignancies, where monitoring and management of inter- and intra-fraction vaginal apex motion is vital. The study monitored vaginal apex motion in real-time and observed large, transient displacements arising from transit of bowel gas and changes in bladder filling during an average treatment time of 11.1 minutes, illustrating the importance of real-time MRI-guidance.

ASTRO's Physics Award: An abstract from researchers at Washington University won ASTRO's Physics Award in the Resident ePoster Recognitions. The presentation by Lauren Henke, M.D., highlighted MRIdian's ability to deliver an SBRT ablative dose (50 Gray in 5 fractions) for oligometastatic or unresectable primary abdominal malignancies while decreasing acute normal tissue toxicities. Daily MR-based imaging revealed motion of the gastrointestinal tract that frequently required re-planning to avoid constraint violation. Quality of life (QOL) was recorded pre-treatment and at 6 weeks and 6 months post treatment. There was no change in pre-treatment and 6-week QOL scores. Additionally, the researchers reported no grade 3 toxicities at 6 weeks or 3 months.

Rad Oncology Homepage